Campbell Rogers Sells 65,153 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 65,153 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $24.49, for a total value of $1,595,596.97. Following the sale, the insider directly owned 76,034 shares in the company, valued at $1,862,072.66. The trade was a 46.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Heartflow Price Performance

Shares of NASDAQ HTFL traded up $1.61 during mid-day trading on Tuesday, reaching $22.27. 2,990,336 shares of the company’s stock were exchanged, compared to its average volume of 1,806,868. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $41.22. The stock has a market capitalization of $1.90 billion and a price-to-earnings ratio of -12.30. The firm’s fifty day moving average is $29.74.

Institutional Trading of Heartflow

A number of large investors have recently added to or reduced their stakes in HTFL. Caitong International Asset Management Co. Ltd bought a new position in shares of Heartflow in the 4th quarter valued at about $27,000. TFC Financial Management Inc. bought a new position in Heartflow during the third quarter worth about $40,000. Russell Investments Group Ltd. acquired a new position in Heartflow during the fourth quarter worth approximately $45,000. Legal & General Group Plc bought a new stake in Heartflow in the third quarter valued at approximately $59,000. Finally, Strs Ohio acquired a new stake in shares of Heartflow in the fourth quarter valued at approximately $99,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HTFL shares. Canaccord Genuity Group increased their price objective on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. lifted their price target on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Stifel Nicolaus upped their price objective on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Finally, Wells Fargo & Company initiated coverage on shares of Heartflow in a report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Heartflow currently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.